
Sign up to save your podcasts
Or


A new study from the NIAID revealed that at least 50% of Covid-19 patients treated with a 5-day dosage of Gilead’s Remdesivir reported improved symptoms and were discharged from the hospital within two weeks. Former FDA Commissioner Dr. Scott Gottlieb describes the treatment as “part of a better toolbox” for fighting the coronavirus, but “not a home run.” Plus, Mindy Grossman, CEO of WW International, (formerly known as Weight Watchers) discusses keeping her business and our bodies well during quarantine.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By CNBC4.2
525525 ratings
A new study from the NIAID revealed that at least 50% of Covid-19 patients treated with a 5-day dosage of Gilead’s Remdesivir reported improved symptoms and were discharged from the hospital within two weeks. Former FDA Commissioner Dr. Scott Gottlieb describes the treatment as “part of a better toolbox” for fighting the coronavirus, but “not a home run.” Plus, Mindy Grossman, CEO of WW International, (formerly known as Weight Watchers) discusses keeping her business and our bodies well during quarantine.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

4,072 Listeners

3,221 Listeners

1,358 Listeners

240 Listeners

150 Listeners

528 Listeners

327 Listeners

68 Listeners

153 Listeners

1,045 Listeners

28 Listeners

350 Listeners

45 Listeners

2,130 Listeners

594 Listeners

5 Listeners

20 Listeners

10,043 Listeners

1,566 Listeners

406 Listeners

303 Listeners

119 Listeners

809 Listeners

159 Listeners

36 Listeners

13 Listeners

30 Listeners

10 Listeners

16 Listeners

0 Listeners